Tag Archives: BeiGene

BeiGene executive Wu Xiaobin sells over $1 million in company stock, a move that has sparked intrigue within the financial world. This transaction, occurring amidst a backdrop of fluctuating market conditions and recent company news, raises questions about potential motivations and implications for both BeiGene and the broader biotech industry. …

Read More »